Harwood A R, Beale F A, Cummings B J, Keane T J, Payne D G, Rider W D, Rawlinson E, Elhakim T
Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):311-9. doi: 10.1016/0360-3016(83)90289-4.
Four hundred and ten patients with supraglottic laryngeal carcinoma treated with moderate dose radical radiotherapy with surgery for salvage (RRSS) were analyzed in detail to determine optimal dose-time-volume parameters to be used in the treatment of each stage of supraglottic carcinoma. In the RRSS group 41% are alive and well at 5 years, 38% died of their tumor and 21% of intercurrent disease. Presence or absence of nodal disease has a major impact on survival. Local control is approximately 70% in T1, T2N0 patients and approximately 50% in T3 and T4N0 patients. Seventeen percent of T1 and T2N0 patients failed in the initially negative neck. Ten major complications (2.4%) have been seen. Local control by irradiation was not influenced by dose or field size. Regional control in the initially negative neck was markedly increased with the use of larger irradiation field sizes. Field sizes of less than 7 X 7 cm resulted in an 18% neck failure rate as compared to 3% with larger field sizes (p = 0.00005). This particularly applied to early stage disease. As a result of the use of larger irradiation field sizes giving reduced neck failure rates, improvement in survival has been seen in early stage supraglottic patients. The results are compared with published results. There is no statistically significant dose response curve in any stage of supraglottic cancer over the dose range 1650-2300 ret. Optimal treatment factors for supraglottic cancer are discussed.
对410例声门上型喉癌患者进行了详细分析,这些患者接受了中等剂量根治性放疗并辅以手术挽救治疗(RRSS),以确定声门上型癌各阶段治疗中使用的最佳剂量-时间-体积参数。在RRSS组中,41%的患者5年时存活且状况良好,38%死于肿瘤,21%死于并发疾病。有无淋巴结疾病对生存有重大影响。T1、T2N0患者的局部控制率约为70%,T3和T4N0患者约为50%。17%的T1和T2N0患者最初颈部阴性但出现失败。已观察到10例主要并发症(2.4%)。照射的局部控制不受剂量或野大小的影响。使用更大的照射野大小可显著提高最初阴性颈部的区域控制率。小于7×7 cm的野大小导致颈部失败率为18%,而更大野大小的失败率为3%(p = 0.00005)。这尤其适用于早期疾病。由于使用更大的照射野大小降低了颈部失败率,早期声门上型患者的生存率有所提高。将结果与已发表的结果进行了比较。在1650 - 2300 ret剂量范围内,声门上型癌的任何阶段均无统计学显著的剂量反应曲线。讨论了声门上型癌的最佳治疗因素。